ARV-806

PreclinicalSmall molecule

AArvinas Inc.

ARV-806 is one of 3 small molecule programs targeting KRAS G12D. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KRAS G12DActive, not recruiting

KRAS G12DPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in KRAS G12D

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

1 2

GFH375

GGenfleet Therapeutics (Shanghai) Inc.

Phase 3

1 3

ARV-806

AArvinas Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalActive, not recruiting

KRAS G12D

NCT07023731

Clinical

Trials by Indication[1]

KRAS G12D1 trial

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Active, not recruiting·AArvinas Inc.·Preclinical·NCT07023731·159 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARV-806. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARV-806 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARV-806. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arvinas Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AArvinas Inc.

ARV-806

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

KRAS G12D1 trial

References

Drug Info

Quick Facts

Related News